MARKET

CLLS

CLLS

Cellectis
NASDAQ
2.699
-0.131
-4.63%
Opening 09:44 02/26 EST
OPEN
2.810
PREV CLOSE
2.830
HIGH
2.810
LOW
2.699
VOLUME
25.67K
TURNOVER
0
52 WEEK HIGH
3.774
52 WEEK LOW
0.9628
MARKET CAP
150.02M
P/E (TTM)
-2.2312
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CLLS last week (0219-0223)?
Weekly Report · 21h ago
Weekly Report: what happened at CLLS last week (0212-0216)?
Weekly Report · 02/19 09:45
Cellectis: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 02/15 02:03
Weekly Report: what happened at CLLS last week (0205-0209)?
Weekly Report · 02/12 09:42
Weekly Report: what happened at CLLS last week (0129-0202)?
Weekly Report · 02/05 09:44
Weekly Report: what happened at CLLS last week (0122-0126)?
Weekly Report · 01/29 09:41
Cellectis: Pushing A Different Kind Of CAR-T Up The Hill
Cellectis S.A. Is a biotech company focused on developing allogeneic CAR T-cell therapy. Their approach uses donor T cells instead of the patient's own cells. They have three main projects in clinical studies, with their most advanced therapy being outlicensed to Allogene. The company has an unproven, promising tech with a long developmental lag time. CLLS is a decided "hold" for me at this time.
Seeking Alpha · 01/22 23:34
Weekly Report: what happened at CLLS last week (0115-0119)?
Weekly Report · 01/22 09:42
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers Cellectis SA (ADR) stock information, including NASDAQ: CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.